The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family

Oncogene

Volumn 32, Issue 13, 2013, Pages 1714-1723

  Skrypek, N ^a,b,c   Duchene B ^a,b,c   Hebbar, M ^a,b,c   Leteurtre, E ^a,b,c   Van Seuningen, I ^a,b,c   Jonckheere, N ^a,b,c  

^a JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^b UNIV LILLE   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Gemcitabine; hCNT1; MUC4; Mucin; NF B; Pancreatic cancer

Indexed keywords

CARRIER PROTEINS AND BINDING PROTEINS; DEOXYCYTIDINE KINASE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 3; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MUCIN 4; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 5; OXIDOREDUCTASE; PROTEIN BAX; PROTEIN BCL XL; RIBONUCLEOTIDE REDUCTASE 1; RIBONUCLEOTIDE REDUCTASE 2; SHORT HAIRPIN RNA; STRESS ACTIVATED PROTEIN KINASE; TETRAZOLIUM; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CELL; CANCER STAGING; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MALE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ADENOCARCINOMA; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; MODELS, BIOLOGICAL; MUCIN-4; MULTIGENE FAMILY; PANCREATIC NEOPLASMS;

EID: 84875887000     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.179     Document Type: Article

References (49)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet 2011; 378: 607-620.
3. O'Reilly EM. Pancreatic adenocarcinoma: New strategies for success. Gastrointest Cancer Res 2009; 3: S11-S15.
4. Damaraju VL, Damaraju S, Young JD, Baldwin SA, Mackey J, Sawyer MB et al. Nucleoside anticancer drugs: The role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene 2003; 22: 7524-7536.
5. Farrell JJ, Elsaleh H, Garcia M, Lai R, Ammar A, Regine WF et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 2009; 136: 187-195.
6. Giovannetti E, Del TM, Mey V, Funel N, Nannizzi S, Ricci S et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res 2006; 66: 3928-3935.
7. Marechal R, Mackey JR, Lai R, Demetter P, Peeters M, Polus M et al. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin Cancer Res 2009; 15: 2913-2919.
8. Bhutia YD, Hung SW, Patel B, Lovin D, Govindarajan R. CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells. Cancer Res 2011; 71: 1825-1835.
9. Garcia-Manteiga J, Molina-Arcas M, Casado FJ, Mazo A, Pastor-Anglada M. Nucleoside transporter profiles in human pancreatic cancer cells: Role of hCNT1 in 20,20-difluorodeoxycytidine- induced cytotoxicity. Clin Cancer Res 2003; 9: 5000-5008.
10. Bafna S, Kaur S, Momi N, Batra SK. Pancreatic cancer cells resistance to gemcitabine: The role of MUC4 mucin. Br J Cancer 2009; 101: 1155-1161.
11. Kalra AV, Campbell RB. Mucin impedes cytotoxic effect of 5-FU against growth of human pancreatic cancer cells: Overcoming cellular barriers for therapeutic gain. Br J Cancer 2007; 97: 910-918.
12. Kalra AV, Campbell RB. Mucin overexpression limits the effectiveness of 5-FU by reducing intracellular drug uptake and antineoplastic drug effects in pancreatic tumours. Eur J Cancer 2009; 45: 164-173.
13. Jonckheere N, Skrypek N, van Seuningen I. Mucins and pancreatic cancer. Cancers 2010; 2: 1794-1812.
14. Chaturvedi P, Singh AP, Moniaux N, Senapati S, Chakraborty S, Meza JL et al. MUC4 mucin potentiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins. Mol Cancer Res 2007; 5: 309-320.
15. Jonckheere N, Skrypek N, Merlin J, Dessein AF, Dumont P, Leteurtre E et al. The mucin MUC4 and its membrane partner ErbB2 regulate biological properties of human CAPAN-2 pancreatic cancer cells via different signalling pathways. PLoS One 2012; 7: E32232.
16. Komatsu M, Tatum L, Altman NH, Carothers Carraway CA, Carraway KL. Potentiation of metastasis by cell surface sialomucin complex (rat MUC4), a multifunctional anti-adhesive glycoprotein. Int J Cancer 2000; 87: 480-486.
17. Ponnusamy MP, Lakshmanan I, Jain M, Das S, Chakraborty S, Dey P et al. MUC4 mucin-induced epithelial to mesenchymal transition: A novel mechanism for metastasis of human ovarian cancer cells. Oncogene 2010; 29: 5741-5754.
18. Workman HC, Sweeney C, Carraway KL 3rd. The membrane mucin Muc4 inhibits apoptosis induced by multiple insults via ErbB2-dependent and ErbB2-independent mechanisms. Cancer Res 2009; 69: 2845-2852.
19. Blackstock AW, Lightfoot H, Case LD, Tepper JE, Mukherji SK, Mitchell BS et al. Tumor uptake and elimination of 20,20-difluoro-20-deoxycytidine (gemcitabine) after deoxycytidine kinase gene transfer: Correlation with in vivo tumor response. Clin Cancer Res 2001; 7: 3263-3268.
20. Marechal R, Mackey JR, Lai R, Demetter P, Peeters M, Polus M et al. Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma. Cancer 2010; 116: 5200-5206.
21. Kruh GD, Belinsky MG. The MRP family of drug efflux pumps. Oncogene 2003; 22: 7537-7552.
22. Jordheim LP, Seve P, Tredan O, Dumontet C. The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. Lancet Oncol 2010; 12: 693-702.
23. Swartz MJ, Batra SK, Varshney GC, Hollingsworth MA, Yeo CJ, Cameron JL et al. MUC4 expression increases progressively in pancreatic intraepithelial neoplasia. Am J Clin Pathol 2002; 117: 791-796.
24. Mackey TJ, Borkowski A, Amin P, Jacobs SC, Kyprianou N. bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer. Urology 1998; 52: 1085-1090.
25. Krajewski S, Krajewska M, Turner BC, Pratt C, Howard B, Zapata JM et al. Prognostic significance of apoptosis regulators in breast cancer. Endocr Relat Cancer 1999; 6: 29-40.
26. Shi X, Liu S, Kleeff J, Friess H, Buchler MW. Acquired resistance of pancreatic cancer cells towards 5-Fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology 2002; 62: 354-362.
27. Ohishi Y, Oda Y, Uchiumi T, Kobayashi H, Hirakawa T, Miyamoto S et al. ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma. Clin Cancer Res 2002; 8: 3767-3775.
28. Oguri T, Isobe T, Fujitaka K, Ishikawa N, Kohno N. Association between expression of the MRP3 gene and exposure to platinum drugs in lung cancer. Int J Cancer 2001; 93: 584-589.
29. Konig J, Hartel M, Nies AT, Martignoni ME, Guo J, Buchler MW et al. Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma. Int J Cancer 2005; 115: 359-367.
30. Chen ZS, Lee K, Kruh GD. Transport of cyclic nucleotides and estradiol 17-beta-Dglucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. J Biol Chem 2001; 276: 33747-33754.
31. Lee K, Klein-Szanto AJ, Kruh GD. Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells. J Natl Cancer Inst 2000; 92: 1934-1940.
32. Hagmann W, Jesnowski R, Lohr JM. Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells. Neoplasia 2010; 12: 740-747.
33. Hu YP, Haq B, Carraway KL, Savaraj N, Lampidis TJ. Multidrug resistance correlates with overexpression of Muc4 but inversely with P-glycoprotein and multidrug resistance related protein in transfected human melanoma cells. Biochem Pharmacol 2003; 65: 1419-1425.
34. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclear factorkappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999; 5: 119-127.
35. Arlt A, Gehrz A, Muerkoster S, Vorndamm J, Kruse ML, Folsch UR et al. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 2003; 22: 3243-3251.
36. Banerjee S, Zhang Y, Ali S, Bhuiyan M, Wang Z, Chiao PJ et al. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res 2005; 65: 9064-9072.
37. Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal BB. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 2007; 67: 3853-3861.
38. Wang SJ, Gao Y, Chen H, Kong R, Jiang HC, Pan SH et al. Dihydroartemisinin inactivates NF-kappaB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo. Cancer Lett 2010; 293: 99-108.
39. Kong R, Sun B, Jiang H, Pan S, Chen H, Wang S et al. Downregulation of nuclear factor-kappaB p65 subunit by small interfering RNA synergizes with gemcitabine to inhibit the growth of pancreatic cancer. Cancer Lett 2010; 291: 90-98.
40. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825.
41. Theile D, Grebhardt S, Haefeli WE, Weiss J. Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy. Biochem Pharmacol 2009; 78: 1366-1373.
42. Tian Q, Zhang J, Tan TM, Chan E, Duan W, Chan SY et al. Human multidrug resistance associated protein 4 confers resistance to camptothecins. Pharm Res 2005; 22: 1837-1853.
43. Jonckheere N, Perrais M, Mariette C, Batra SK, Aubert JP, Pigny P et al. A role for human MUC4 mucin gene, the ErbB2 ligand, as a target of TGF-beta in pancreatic carcinogenesis. Oncogene 2004; 23: 5729-5738.
44. Van Seuningen I, Ostrowski J, Bustelo XR, Sleath PR, Bomsztyk K. The K protein domain that recruits the interleukin 1-responsive K protein kinase lies adjacent to a cluster of c-Src and Vav SH3-binding sites. Implications that K protein acts as a docking platform. J Biol Chem 1995; 270: 26976-26985.
45. Jonckheere N, Fauquette V, Stechly L, Saint-Laurent N, Aubert S, Susini C et al. Tumour growth and resistance to gemcitabine of pancreatic cancer cells are decreased by AP-2alpha overexpression. Br J Cancer 2009; 101: 637-644.
46. Piessen G, Jonckheere N, Vincent A, Hemon B, Ducourouble MP, Copin MC et al. Regulation of the human mucin MUC4 by taurodeoxycholic and taurochenodeoxycholic bile acids in oesophageal cancer cells is mediated by hepatocyte nuclear factor 1alpha. Biochem J 2007; 402: 81-91.
47. Van Seuningen I, Perrais M, Pigny P, Porchet N, Aubert JP. Sequence of the 50-flanking region and promoter activity of the human mucin gene MUC5B in different phenotypes of colon cancer cells. Biochem J 2000; 348: 675-686.
48. van der Sluis M, Melis MH, Jonckheere N, Ducourouble MP, Buller HA, Renes I et al. The murine Muc2 mucin gene is transcriptionally regulated by the zinc-finger GATA-4 transcription factor in intestinal cells. Biochem Biophys Res Commun 2004; 325: 952-960.
49. Mariette C, Perrais M, Leteurtre E, Jonckheere N, Hemon B, Pigny P et al. Transcriptional regulation of human mucin MUC4 by bile acids in oesophageal cancer cells is promoter-dependent and involves activation of the phosphatidylinositol 3-kinase signalling pathway. Biochem J 2004; 377: 701-708.